ArticleChinese journal of integrative medicine2026
Both Gut Microbiota-Dependent and -Independent Constituents of Xinglou Chengqi Decoction Highlight Flavin Adenine Dinucleotide in Treatment of Severe Traumatic Brain Injury.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of Xinglou Chengqi Decoction (XCD) on severe traumatic brain injury (sTBI) and its relationship with gut microbiota.
methodsC57BL/6J mice were randomly allocated into sham, controlled cortical impact (CCI), and 3 doses of XCD (4.1, 8.2, and 16.4 g/kg) groups by using a random number table, n=7 per group. A CCI device was employed to establish the TBI model. XCD was administered intragastrically for 3 consecutive days. The effects of XCD on post-sTBI neurological deficits and histopathology were assessed. The contribution of gut microbiota to XCD-mediated improvement in sTBI was investigated using antibiotic-treated TBI mice. The gut microbiota-dependent mechanisms of XCD in sTBI were explored through 16S rDNA sequencing and serum metabolomics. The mechanisms underlying the absorbed ingredients of XCD in sTBI were examined using network pharmacology and metabolomics. Finally, mice were divided into sham, CCI, and flavin adenine dinucleotide (FAD)-treated groups, n=10 per group. FAD was administered to sTBI mice via daily tail vein injection (830 µg/kg) for 3 consecutive days to evaluate and verify its therapeutic effect.
resultsXCD significantly mitigated neurological impairments, neuronal damage, apoptosis, and blood-brain barrier disruption in CCI model mice (P<0.05 or P<0.01). The medium dose (8.2 g/kg) exhibited the greatest effect. The gut microbiota partly contributed to these protective effects. 16S rDNA sequencing indicated that XCD promoted beneficial gut microbiota. Metabolomic analysis demonstrated that XCD regulated serum metabolic profiles, particularly FAD. Network pharmacology combined with metabolomics analysis revealed that the gut microbiota-independent components of XCD also targeted FAD in TBI. FAD exerted neuroprotective effects, improved energy metabolism, and promoted angiogenesis following TBI (P<0.05 or P<0.01).
conclusionXCD exerts neuroprotective effects on sTBI through both gut microbiota-dependent and -independent mechanisms, which highlight the therapeutic role of FAD.
Indexed as
Identifiers
40938502What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.